- Investing Ideas
- Global Biotech Breakthroughs
Global Biotech Breakthroughs
Results
86
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
86 companies
Madrigal Pharmaceuticals
Market Cap: US$12.4b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$534.86
7D
3.4%
1Y
78.5%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$104.3b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$447.20
7D
-4.7%
1Y
39.3%
Beijing Luzhu Biotechnology
Market Cap: HK$4.4b
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China.
2480
HK$22.08
7D
-4.8%
1Y
3.2%
Dizal (Jiangsu) Pharmaceutical
Market Cap: CN¥25.3b
A commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders.
688192
CN¥54.32
7D
-4.2%
1Y
-3.7%
CARsgen Therapeutics Holdings
Market Cap: HK$12.5b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$23.28
7D
7.8%
1Y
37.9%
Ascelia Pharma
Market Cap: SEK 396.6m
A biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.
ACE
SEK 2.86
7D
-4.8%
1Y
-25.9%
Precigen
Market Cap: US$1.6b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.15
7D
-0.2%
1Y
207.4%
Syndax Pharmaceuticals
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$20.54
7D
-4.2%
1Y
86.6%
Insmed
Market Cap: US$29.6b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$104.80
7D
-23.1%
1Y
59.7%
Guangzhou Innogen Pharmaceutical Group
Market Cap: HK$5.8b
Engages in the development of drugs.
2591
HK$12.65
7D
-9.6%
1Y
n/a
HansBiomed
Market Cap: ₩359.4b
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.
A042520
₩25,200.00
7D
-14.3%
1Y
252.0%
AnaptysBio
Market Cap: US$1.9b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$66.96
7D
1.9%
1Y
242.0%
Marker Therapeutics
Market Cap: US$24.3m
A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
MRKR
US$1.44
7D
-1.4%
1Y
12.5%
Akeso
Market Cap: HK$123.4b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$134.00
7D
-1.3%
1Y
58.9%
Ardelyx
Market Cap: US$1.8b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.98
7D
10.3%
1Y
91.8%
Keymed Biosciences
Market Cap: HK$21.2b
A biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally.
2162
HK$71.95
7D
-4.8%
1Y
71.1%
BioPorto
Market Cap: DKK 586.7m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.
BIOPOR
DKK 1.15
7D
-7.3%
1Y
-24.0%
3billion
Market Cap: ₩369.1b
Develops technology for rare disease drug discovery using bioinformatics and machine learning technology.
A394800
₩11,620.00
7D
-14.0%
1Y
69.1%
Cutia Therapeutics
Market Cap: HK$1.7b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$4.58
7D
-0.4%
1Y
-26.1%
Guard Therapeutics International
Market Cap: SEK 21.7m
A clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden.
GUARD
SEK 1.19
7D
12.1%
1Y
-91.5%
Mesoblast
Market Cap: AU$2.6b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.02
7D
-8.2%
1Y
18.5%
RenovoRx
Market Cap: US$40.1m
A clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.88
7D
3.5%
1Y
-15.4%
Aldeyra Therapeutics
Market Cap: US$105.0m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.73
7D
13.8%
1Y
-19.9%
Capricor Therapeutics
Market Cap: US$2.0b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$33.94
7D
1.1%
1Y
386.9%
X4 Pharmaceuticals
Market Cap: US$398.2m
A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
XFOR
US$4.29
7D
5.4%
1Y
30.4%
Pelthos Therapeutics
Market Cap: US$83.9m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$25.03
7D
0.1%
1Y
123.5%
Tenaya Therapeutics
Market Cap: US$171.5m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$0.85
7D
22.8%
1Y
92.6%
Revolution Medicines
Market Cap: US$32.1b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$142.51
7D
-1.1%
1Y
240.0%
ARS Pharmaceuticals
Market Cap: US$921.5m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$9.00
7D
9.0%
1Y
-33.3%
Lineage Cell Therapeutics
Market Cap: US$356.2m
A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
LCTX
US$1.37
7D
-9.3%
1Y
191.5%
Ascentage Pharma Group International
Market Cap: HK$15.7b
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
6855
HK$42.64
7D
-4.5%
1Y
-10.2%
DBV Technologies
Market Cap: €994.3m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€3.40
7D
-6.2%
1Y
90.4%
Citius Oncology
Market Cap: US$80.3m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$0.90
7D
2.4%
1Y
6.6%
CG Oncology
Market Cap: US$6.0b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$69.18
7D
3.7%
1Y
186.7%
Arcutis Biotherapeutics
Market Cap: US$3.0b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$20.66
7D
-11.0%
1Y
52.9%
Lipigon Pharmaceuticals
Market Cap: SEK 2.4m
A clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden.
LPGO
SEK 0.0036
7D
44.0%
1Y
-96.2%